Dr. Soon-Shiong to Launch ImmunityBio, an Immunotherapy Company at Upcoming Jefferies 2019 Annual Healthcare Conference

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, a privately held immunotherapy company at late stage clinical development, that aims to synergistically deploy a broad portfolio of biological molecules as an integrated cancer vaccine platform targeting multiple tumor types without the use of high-dose chemotherapy, today announced that Dr. Patrick Soon-Shiong will be presenting at the Jefferies 2019 Annual Healthcare Conference being held in New York City from June 4^th-7^th, 2019. The presentation and one-on-one discussions will launch the privately held company with a portfolio of over 20 first in class biological molecules deployed to orchestrate the innate and adaptive immune system, and will feature clinical updates of multiple trials with registrational intent.

Conference Details:

Event: Jefferies 2019 Annual Healthcare Conference

Date/Time: Tuesday, June 4, 2019, Presentation at 8:00am ET

Location: New York, NY

For more information regarding ImmunityBio please visit www.ImmunityBio.com

About ImmunityBio

ImmunityBio, is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptide, fusion protein, cytokine, monoclonal antibody, adenovirus and yeast vaccine therapies.

This platform of technologies has enabled ImmunityBio to achieve one of the most comprehensive late stage clinical pipelines addressing both the innate (activated macrophage and natural killer cell) and the adaptive immune system (dendritic, CD4 and CD8 killer T cells). The pipeline constitutes over 40 immunological assets with 13 first in human immunotherapy molecules in active clinical trials. In 2019, ImmunityBio is planning the enrollment of patients in late stage trials with 3 molecules across 17 indications in solid and liquid tumors.

In the field of oncology, ImmunityBio’s goal is to employ a broad portfolio of biological molecules that will enable it to activate endogenous NK and CD8+ T cells, and develop a T cell memory cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy.

In the field of infectious disease, ImmunityBio’s goal is to develop vaccine therapy for the prevention and treatment of Influenza, Zika, Ebola and HIV.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning or implying that ImmunityBio will be successful in improving the treatment of cancer. Risks and uncertainties related to this endeavor include, but are not limited to, obtaining FDA approval of ImmunityBio’s IL-15 based Cytokine therapy, N-803,and other therapeutics as part of the ImmunityBio portfolio.

Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005397/en/